Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Keith Alan Johnson, M.D.

Co-Author

This page shows the publications co-authored by Keith Johnson and Dorene Rentz.
Connection Strength

10.852
  1. Association of Digital Clock Drawing With PET Amyloid and Tau Pathology in Normal Older Adults. Neurology. 2021 04 06; 96(14):e1844-e1854.
    View in: PubMed
    Score: 0.948
  2. Cognitive resilience in clinical and preclinical Alzheimer's disease: the Association of Amyloid and Tau Burden on cognitive performance. Brain Imaging Behav. 2017 04; 11(2):383-390.
    View in: PubMed
    Score: 0.724
  3. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol. 2010 Mar; 67(3):353-64.
    View in: PubMed
    Score: 0.443
  4. Intelligence quotient-adjusted memory impairment is associated with abnormal single photon emission computed tomography perfusion. J Int Neuropsychol Soc. 2007 Sep; 13(5):821-31.
    View in: PubMed
    Score: 0.373
  5. In vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimer's disease pathology and cognitive decline. Sci Transl Med. 2021 09 22; 13(612):eabj2511.
    View in: PubMed
    Score: 0.247
  6. The cortical origin and initial spread of medial temporal tauopathy in Alzheimer's disease assessed with positron emission tomography. Sci Transl Med. 2021 01 20; 13(577).
    View in: PubMed
    Score: 0.236
  7. The presubiculum links incipient amyloid and tau pathology to memory function in older persons. Neurology. 2020 05 05; 94(18):e1916-e1928.
    View in: PubMed
    Score: 0.223
  8. Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. JAMA Neurol. 2019 Aug 01; 76(8):915-924.
    View in: PubMed
    Score: 0.213
  9. The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann Neurol. 2019 02; 85(2):181-193.
    View in: PubMed
    Score: 0.205
  10. Measuring instrumental activities of daily living in non-demented elderly: a comparison of the new performance-based Harvard Automated Phone Task with other functional assessments. Alzheimers Res Ther. 2019 01 10; 11(1):4.
    View in: PubMed
    Score: 0.205
  11. Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease Dementia. J Alzheimers Dis. 2019; 67(2):757-768.
    View in: PubMed
    Score: 0.204
  12. Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat Neurosci. 2018 03; 21(3):424-431.
    View in: PubMed
    Score: 0.192
  13. Neuroimaging markers associated with maintenance of optimal memory performance in late-life. Neuropsychologia. 2017 06; 100:164-170.
    View in: PubMed
    Score: 0.182
  14. Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline. Ann Neurol. 2017 Apr; 81(4):583-596.
    View in: PubMed
    Score: 0.181
  15. Activities of daily living measured by the Harvard Automated Phone Task track with cognitive decline over time in non-demented elderly. J Prev Alzheimers Dis. 2017; 4(2):81-86.
    View in: PubMed
    Score: 0.178
  16. Maternal dementia age at onset in relation to amyloid burden in non-demented elderly offspring. Neurobiol Aging. 2016 Apr; 40:61-67.
    View in: PubMed
    Score: 0.166
  17. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016 Jan; 79(1):110-9.
    View in: PubMed
    Score: 0.166
  18. The Harvard Automated Phone Task: new performance-based activities of daily living tests for early Alzheimer's disease. J Prev Alzheimers Dis. 2015 Dec; 2(4):242-253.
    View in: PubMed
    Score: 0.165
  19. Biomarker validation of a decline in semantic processing in preclinical Alzheimer's disease. Neuropsychology. 2016 07; 30(5):624-30.
    View in: PubMed
    Score: 0.165
  20. Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers. Neurology. 2015 Jul 07; 85(1):48-55.
    View in: PubMed
    Score: 0.160
  21. Subjective cognitive concerns, amyloid-ß, and neurodegeneration in clinically normal elderly. Neurology. 2015 Jul 07; 85(1):56-62.
    View in: PubMed
    Score: 0.160
  22. Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease. Neuropsychologia. 2015 Jul; 73:169-75.
    View in: PubMed
    Score: 0.159
  23. Functional Activities Questionnaire Items that Best Discriminate and Predict Progression from Clinically Normal to Mild Cognitive Impairment. Curr Alzheimer Res. 2015; 12(5):493-502.
    View in: PubMed
    Score: 0.155
  24. Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease. Am J Geriatr Psychiatry. 2014 Dec; 22(12):1642-51.
    View in: PubMed
    Score: 0.146
  25. Apathy is associated with increased amyloid burden in mild cognitive impairment. J Neuropsychiatry Clin Neurosci. 2013; 25(4):302-7.
    View in: PubMed
    Score: 0.135
  26. Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. J Neurosci. 2012 Nov 14; 32(46):16233-42.
    View in: PubMed
    Score: 0.134
  27. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia. 2012 Oct; 50(12):2880-2886.
    View in: PubMed
    Score: 0.132
  28. Instrumental activities of daily living impairment is associated with increased amyloid burden. Dement Geriatr Cogn Disord. 2011; 31(6):443-50.
    View in: PubMed
    Score: 0.122
  29. Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia. 2011 Jul; 49(9):2776-83.
    View in: PubMed
    Score: 0.121
  30. Amyloid-ß associated cortical thinning in clinically normal elderly. Ann Neurol. 2011 Jun; 69(6):1032-42.
    View in: PubMed
    Score: 0.119
  31. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc Natl Acad Sci U S A. 2010 Jun 01; 107(22):10256-61.
    View in: PubMed
    Score: 0.112
  32. Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med. 2010 Mar; 12(1):27-43.
    View in: PubMed
    Score: 0.111
  33. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009 Jul 30; 63(2):178-88.
    View in: PubMed
    Score: 0.106
  34. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007 Sep; 62(3):229-34.
    View in: PubMed
    Score: 0.093
  35. Unsupervised mobile cognitive testing for use in preclinical Alzheimer's disease. Alzheimers Dement (Amst). 2021; 13(1):e12243.
    View in: PubMed
    Score: 0.062
  36. Plasma IL-12/IFN-? axis predicts cognitive trajectories in cognitively unimpaired older adults. Alzheimers Dement. 2021 Jun 23.
    View in: PubMed
    Score: 0.061
  37. Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease. Neurology. 2021 May 05.
    View in: PubMed
    Score: 0.060
  38. Diminished Learning Over Repeated Exposures (LORE) in preclinical Alzheimer's disease. Alzheimers Dement (Amst). 2020; 12(1):e12132.
    View in: PubMed
    Score: 0.059
  39. Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation. Neurology. 2021 01 26; 96(4):e619-e631.
    View in: PubMed
    Score: 0.058
  40. Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study. Alzheimers Dement (Amst). 2020; 12(1):e12118.
    View in: PubMed
    Score: 0.058
  41. Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. Alzheimers Res Ther. 2020 10 29; 12(1):138.
    View in: PubMed
    Score: 0.058
  42. Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. J Int Neuropsychol Soc. 2021 05; 27(5):426-438.
    View in: PubMed
    Score: 0.058
  43. Correction: Association of anxiety with subcortical amyloidosis in cognitively normal older adults. Mol Psychiatry. 2020 Oct; 25(10):2644.
    View in: PubMed
    Score: 0.058
  44. The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's disease. Alzheimers Res Ther. 2020 09 10; 12(1):104.
    View in: PubMed
    Score: 0.057
  45. Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline. Ann Neurol. 2020 11; 88(5):921-932.
    View in: PubMed
    Score: 0.057
  46. Multiple markers contribute to risk of progression from normal to mild cognitive impairment. Neuroimage Clin. 2020; 28:102400.
    View in: PubMed
    Score: 0.057
  47. Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer's disease. Alzheimers Res Ther. 2020 08 21; 12(1):99.
    View in: PubMed
    Score: 0.057
  48. Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers. Neurology. 2020 09 08; 95(10):e1312-e1321.
    View in: PubMed
    Score: 0.057
  49. Amyloid-beta burden predicts prospective decline in body mass index in clinically normal adults. Neurobiol Aging. 2020 09; 93:124-130.
    View in: PubMed
    Score: 0.055
  50. Associations of Widowhood and ß-Amyloid With Cognitive Decline in Cognitively Unimpaired Older Adults. JAMA Netw Open. 2020 02 05; 3(2):e200121.
    View in: PubMed
    Score: 0.055
  51. Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. Alzheimers Dement. 2020 03; 16(3):552-560.
    View in: PubMed
    Score: 0.055
  52. Examining Cognitive Decline Across Black and White Participants in the Harvard Aging Brain Study. J Alzheimers Dis. 2020; 75(4):1437-1446.
    View in: PubMed
    Score: 0.055
  53. Association of subjective cognitive decline with markers of brain pathology in preclinical autosomal dominant Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2020 03; 91(3):330-332.
    View in: PubMed
    Score: 0.055
  54. Decreased meta-memory is associated with early tauopathy in cognitively unimpaired older adults. Neuroimage Clin. 2019; 24:102097.
    View in: PubMed
    Score: 0.054
  55. Associations of Physical Activity and ß-Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults. JAMA Neurol. 2019 Oct 01; 76(10):1203-1210.
    View in: PubMed
    Score: 0.054
  56. Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study. Alzheimers Dement (Amst). 2019 Dec; 11:670-678.
    View in: PubMed
    Score: 0.054
  57. Longitudinal Association of Depression Symptoms With Cognition and Cortical Amyloid Among Community-Dwelling Older Adults. JAMA Netw Open. 2019 08 02; 2(8):e198964.
    View in: PubMed
    Score: 0.053
  58. Anticholinergic Amnesia is Mediated by Alterations in Human Network Connectivity Architecture. Cereb Cortex. 2019 07 22; 29(8):3445-3456.
    View in: PubMed
    Score: 0.053
  59. Social Engagement and Amyloid-ß-Related Cognitive Decline in Cognitively Normal Older Adults. Am J Geriatr Psychiatry. 2019 11; 27(11):1247-1256.
    View in: PubMed
    Score: 0.052
  60. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults. JAMA Neurol. 2019 05 01; 76(5):542-551.
    View in: PubMed
    Score: 0.052
  61. Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. Neurobiol Aging. 2019 06; 78:178-185.
    View in: PubMed
    Score: 0.052
  62. Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease. Alzheimers Res Ther. 2019 01 31; 11(1):14.
    View in: PubMed
    Score: 0.051
  63. Vascular Risk and ß-Amyloid Are Synergistically Associated with Cortical Tau. Ann Neurol. 2019 02; 85(2):272-279.
    View in: PubMed
    Score: 0.051
  64. An UNC5C Allele Predicts Cognitive Decline and Hippocampal Atrophy in Clinically Normal Older Adults. J Alzheimers Dis. 2019; 68(3):1161-1170.
    View in: PubMed
    Score: 0.051
  65. Regional tau pathology and loneliness in cognitively normal older adults. Transl Psychiatry. 2018 12 18; 8(1):282.
    View in: PubMed
    Score: 0.051
  66. Amyloid-associated increases in longitudinal report of subjective cognitive complaints. Alzheimers Dement (N Y). 2018; 4:444-449.
    View in: PubMed
    Score: 0.050
  67. Interactive Associations of Vascular Risk and ß-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study. JAMA Neurol. 2018 09 01; 75(9):1124-1131.
    View in: PubMed
    Score: 0.050
  68. Association of anxiety with subcortical amyloidosis in cognitively normal older adults. Mol Psychiatry. 2020 10; 25(10):2599-2607.
    View in: PubMed
    Score: 0.050
  69. Sex, amyloid, and APOE e4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. Alzheimers Dement. 2018 09; 14(9):1193-1203.
    View in: PubMed
    Score: 0.049
  70. PET staging of amyloidosis using striatum. Alzheimers Dement. 2018 10; 14(10):1281-1292.
    View in: PubMed
    Score: 0.049
  71. Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults. Am J Psychiatry. 2018 06 01; 175(6):530-537.
    View in: PubMed
    Score: 0.048
  72. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global ß-Amyloid Burden. JAMA Neurol. 2017 12 01; 74(12):1455-1463.
    View in: PubMed
    Score: 0.047
  73. The relationship between recall of recently versus remotely encoded famous faces and amyloidosis in clinically normal older adults. Alzheimers Dement (Amst). 2018; 10:121-129.
    View in: PubMed
    Score: 0.047
  74. Functional network integrity presages cognitive decline in preclinical Alzheimer disease. Neurology. 2017 Jul 04; 89(1):29-37.
    View in: PubMed
    Score: 0.046
  75. Anosognosia for memory deficits in mild cognitive impairment: Insight into the neural mechanism using functional and molecular imaging. Neuroimage Clin. 2017; 15:408-414.
    View in: PubMed
    Score: 0.046
  76. Hippocampal hypometabolism in older adults with memory complaints and increased amyloid burden. Neurology. 2017 May 02; 88(18):1759-1767.
    View in: PubMed
    Score: 0.045
  77. Memory self-awareness in the preclinical and prodromal stages of Alzheimer's disease. Neuropsychologia. 2017 05; 99:343-349.
    View in: PubMed
    Score: 0.045
  78. Cued memory decline in biomarker-defined preclinical Alzheimer disease. Neurology. 2017 Apr 11; 88(15):1431-1438.
    View in: PubMed
    Score: 0.045
  79. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid ß. Alzheimers Dement. 2017 Sep; 13(9):1004-1012.
    View in: PubMed
    Score: 0.045
  80. Regional 18F-Fluorodeoxyglucose Hypometabolism is Associated with Higher Apathy Scores Over Time in Early Alzheimer Disease. Am J Geriatr Psychiatry. 2017 Jul; 25(7):683-693.
    View in: PubMed
    Score: 0.045
  81. Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A Pilot Study. J Alzheimers Dis. 2017; 59(3):975-985.
    View in: PubMed
    Score: 0.045
  82. Association of Higher Cortical Amyloid Burden With Loneliness in Cognitively Normal Older Adults. JAMA Psychiatry. 2016 Dec 01; 73(12):1230-1237.
    View in: PubMed
    Score: 0.044
  83. The influence of demographic factors on subjective cognitive concerns and beta-amyloid. Int Psychogeriatr. 2017 04; 29(4):645-652.
    View in: PubMed
    Score: 0.044
  84. Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. JAMA Neurol. 2016 Oct 01; 73(10):1185-1191.
    View in: PubMed
    Score: 0.044
  85. Lower Late-Life Body-Mass Index is Associated with Higher Cortical Amyloid Burden in Clinically Normal Elderly. J Alzheimers Dis. 2016 06 18; 53(3):1097-105.
    View in: PubMed
    Score: 0.043
  86. Odor identification and Alzheimer disease biomarkers in clinically normal elderly. Neurology. 2015 May 26; 84(21):2153-60.
    View in: PubMed
    Score: 0.040
  87. Harvard Aging Brain Study: Dataset and accessibility. Neuroimage. 2017 01; 144(Pt B):255-258.
    View in: PubMed
    Score: 0.039
  88. Amyloid-ß deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain. 2015 Apr; 138(Pt 4):1023-35.
    View in: PubMed
    Score: 0.039
  89. Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults. J Alzheimers Dis. 2015; 46(1):63-73.
    View in: PubMed
    Score: 0.039
  90. Neuropsychiatric Symptoms and Functional Connectivity in Mild Cognitive Impairment. J Alzheimers Dis. 2015; 46(3):727-35.
    View in: PubMed
    Score: 0.039
  91. Vascular disease and risk factors are associated with cognitive decline in the alzheimer disease spectrum. Alzheimer Dis Assoc Disord. 2015 Jan-Mar; 29(1):18-25.
    View in: PubMed
    Score: 0.039
  92. The Apathy Evaluation Scale: A Comparison of Subject, Informant, and Clinician Report in Cognitively Normal Elderly and Mild Cognitive Impairment. J Alzheimers Dis. 2015; 47(2):421-32.
    View in: PubMed
    Score: 0.039
  93. Apathy is associated with lower inferior temporal cortical thickness in mild cognitive impairment and normal elderly individuals. J Neuropsychiatry Clin Neurosci. 2015; 27(1):e22-7.
    View in: PubMed
    Score: 0.038
  94. Synergistic effect of ß-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014 Nov; 71(11):1379-85.
    View in: PubMed
    Score: 0.038
  95. Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an (11)C altropane positron emission tomography study. Alzheimers Res Ther. 2014; 6(5-8):52.
    View in: PubMed
    Score: 0.038
  96. Amyloid and APOE e4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014 May 20; 82(20):1760-7.
    View in: PubMed
    Score: 0.037
  97. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014 Mar 19; 6(228):228fs13.
    View in: PubMed
    Score: 0.037
  98. Regional cortical thinning and cerebrospinal biomarkers predict worsening daily functioning across the Alzheimer's disease spectrum. J Alzheimers Dis. 2014; 41(3):719-28.
    View in: PubMed
    Score: 0.036
  99. Everyday cognition scale items that best discriminate between and predict progression from clinically normal to mild cognitive impairment. Curr Alzheimer Res. 2014; 11(9):853-61.
    View in: PubMed
    Score: 0.036
  100. Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer's disease spectrum. J Alzheimers Dis. 2014; 42(1):291-300.
    View in: PubMed
    Score: 0.036
  101. SIST-M-IR activities of daily living items that best discriminate clinically normal elderly from those with mild cognitive impairment. Curr Alzheimer Res. 2014; 11(8):785-91.
    View in: PubMed
    Score: 0.036
  102. Regional cortical thinning predicts worsening apathy and hallucinations across the Alzheimer disease spectrum. Am J Geriatr Psychiatry. 2014 Nov; 22(11):1168-79.
    View in: PubMed
    Score: 0.035
  103. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology. 2013 Jan 01; 80(1):85-91.
    View in: PubMed
    Score: 0.034
  104. Neuropsychiatric symptoms and global functional impairment along the Alzheimer's continuum. Dement Geriatr Cogn Disord. 2012; 34(2):96-111.
    View in: PubMed
    Score: 0.033
  105. Brain amyloid and cognition in Lewy body diseases. Mov Disord. 2012 Jul; 27(8):965-73.
    View in: PubMed
    Score: 0.032
  106. Executive function and instrumental activities of daily living in mild cognitive impairment and Alzheimer's disease. Alzheimers Dement. 2011 May; 7(3):300-8.
    View in: PubMed
    Score: 0.030
  107. Age and amyloid-related alterations in default network habituation to stimulus repetition. Neurobiol Aging. 2012 Jul; 33(7):1237-52.
    View in: PubMed
    Score: 0.030
  108. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007 Jun 06; 27(23):6174-84.
    View in: PubMed
    Score: 0.023
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.